Issue 29, 2020

GS-5734: a potentially approved drug by FDA against SARS-Cov-2

Abstract

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. COVID-19 is an ongoing global health crisis. Efficacious drugs against COVID-19 are not yet available. Therefore, rapid discovery of safe and efficacious agents against SARS-CoV-2 are needed urgently. Nucleoside analogs have an integral role in the treatment of viral infections. Owing to their broad-spectrum antiviral activities, C-nucleoside analogs have become key components of COVID-19 treatment regimens. Here, we review the state-of-the-art C-nucleoside GS-5734 (remdesivir) that is in preclinical research for COVID-19 treatment. As a potentially approved drug by the FDA against SARS-Cov-2 infection, the efficacy and safety of GS-5734 have been documented repeatedly in vitro, in animal models, and in humans. To better understand the drug-development process, this review focused on the discovery process, preparation methods, broad-spectrum activities, and antiviral mechanism of GS-5734.

Graphical abstract: GS-5734: a potentially approved drug by FDA against SARS-Cov-2

Article information

Article type
Perspective
Submitted
28 5月 2020
Accepted
29 6月 2020
First published
01 7月 2020

New J. Chem., 2020,44, 12417-12429

GS-5734: a potentially approved drug by FDA against SARS-Cov-2

Z. Wang and L. Yang, New J. Chem., 2020, 44, 12417 DOI: 10.1039/D0NJ02656E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements